Key result
Immunosuppressive therapy in post-COVID myocarditis is linked to borderline reductions in antinuclear factor titers.
Why the study?
The study aimed to investigate the spectrum of rhythm and conduction disorders in patients with the arrhythmic variant of post-COVID myocarditis and determine treatment approaches.
Does immunosuppressive therapy combined with antiarrhythmic drugs improve rhythm disorders and immunological markers in patients with the arrhythmic variant of post-COVID myocarditis?
Population
23 patients with post-COVID arrhythmias and criteria for myocarditis
Comparison
Methylprednisolone vs hydroxychloroquine immunosuppression combined with antiarrhythmic therapy
Design
Observational cohort study
Authors
Loading...
Maps post-COVID myocarditis arrhythmias in small cohort; hypothesis-generating, requires larger prospective studies before practice implications.
Observational (n=23)
Does immunosuppressive therapy combined with antiarrhythmic drugs improve rhythm disorders and immunological markers in patients with the arrhythmic variant of post-COVID myocarditis?
p-value: p=0.057
Immunosuppressive therapy with methylprednisolone or hydroxychloroquine may facilitate the regression of arrhythmias and reduce immunological activity in patients with post-COVID myocarditis.
Savina et al. (2023) conducted an observational in Post-COVID myocarditis (n=23). Immunosuppressive therapy (methylprednisolone or hydroxychloroquine) was evaluated on Decrease in specific antinuclear factor (ANF) titer (p=0.057). Immunosuppressive therapy with methylprednisolone or hydroxychloroquine in post-COVID myocarditis was associated with a near-significant decrease in specific antinuclear factor titers (p=0.057).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: